- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05321563
Evaluating the Effectiveness of a Drug Education and Diversion Program for Middle and High School Students (iDECIDE)
Study Overview
Status
Intervention / Treatment
Detailed Description
The primary goal of this study is to evaluate the effectiveness of the iDECIDE curriculum as an alternative to punitive responses for school-based substance use infractions. To accomplish this aim, investigators will conduct a Type 1, hybrid effectiveness-implementation trial. Using a stepped wedge design, investigators will randomly allocate the timing of implementation of the iDECIDE curriculum compared to standard disciplinary response, over approximately 24 months. Investigators are testing the overarching hypothesis that student-level outcomes improve when schools transition from a standard disciplinary response to having access to a more educational and therapeutic alternative. Participants for this aim will include students referred by schools with substance use infractions who are assessed by the study team at baseline (proximal to the time of infraction), 45, and 90 days later.
Exploratory aims of this study include:
- Change in school environment -- Evaluating the impact of transition from punitive responses for substance use to iDECIDE on overall prevalence of substance use and perceptions of school culture. Participants for this exploratory aim include all students within participating schools (not just those with substance use infractions), assessed annually beginning Fall 2022.
- Single arm pre/post change -- Evaluating change from session 1 to session 4 of iDECIDE in perceptions of harm from substance use, knowledge of drug effects, perceptions of a supportive school culture, plans to change substance use, and frequency of past 7-day substance use in all students who complete the iDECIDE curriculum. Investigators will also explore whether any change in these outcomes differ among historically underserved populations, including racial and gender minority students. Participants for this exploratory aim incIude all students who participate in the iDECIDE curriculum, regardless of the reason for referral into the program and the provision of parental consent for collection of data for primary aims.
- Identification of implementation barriers -- Evaluating the feasibility and acceptability of the iDECIDE curriculum by identifying multi-level barriers and facilitators to implementation using mixed methods. Participants for this exploratory aim include school stakeholders, interviewed right before and 6 months following iDECIDE implementation.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Eligibility criteria for the primary aim (i.e., evaluating how student-level outcomes change when schools transition from a standard disciplinary response to having access to a more educational and therapeutic alternative):
Inclusion Criteria:
- Enrolled in a participating middle or high school;
- Received a substance use-related infraction at school or school-sanctioned event;
- Have a parent or legal guardian who is able and willing to provide written informed consent (if under the age of 18);
- Competent and willing to provide written informed consent (if age 18+) or assent (if under 18);
- Able to read and write comfortably in English;
- In the opinion of the investigator, able to safely participate in the protocol.
Exclusion Criteria:
- Passive consent for referral to MGH evaluation team declined by parent or legal guardian;
- Gross cognitive impairment, for example due to florid psychosis, intellectual disability, developmental delay, or neurodegenerative disease;
- Ward of the state.
Eligibility criteria for participants for exploratory aims:
In addition to the students with school-based substance use infractions enrolled for the primary aims, three additional cohorts of participants will be recruited for exploratory aims. The eligibility criteria for these cohorts are listed below.
Exploratory Aim 1: evaluating the impact of transition from punitive responses for substance use to iDECIDE on overall prevalence of substance use and perceptions of school culture (Annual School-Wide Assessment)
Inclusion Criteria:
- Currently enrolled in a participating middle or high school;
- Provide informed assent/consent for participation in this research by voluntarily completing the survey.
Exclusion Criteria:
- Passive consent for school-wide assessment declined by parent or legal guardian;
- Not able to adequately read and respond to survey items in one of the languages available.
Exploratory Aim 2: Evaluating change from session 1 to session 4 of iDECIDE in perceptions of harm from substance use, knowledge of drug effects, perceptions of a supportive school culture, plans to change substance use, and frequency of past 7-day substance use in all students who complete the iDECIDE curriculum.
Inclusion Criteria:
- Enrolled in the iDECIDE curriculum by a trained iDECIDE facilitator.
Exclusion Criteria:
- Unable to adequately read and respond to survey items in one of the languages available.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Observation Phase
Schools will continue to apply their standard disciplinary response to school-based substance use infractions during the 'unexposed' study period.
|
|
|
Experimental: Intervention Phase
Schools will have the opportunity to deliver the iDECIDE curriculum in lieu of or as part of the standard disciplinary response to school-based substance use infractions during the 'exposed' study period.
|
iDECIDE is a 4 session curriculum that addresses topics such as the neurobiology of substance use, adolescent brain development, industry tactics, motivations for using substances, risk and protective factors, triggers, healthy alternatives, core values, and long-term goal setting.
These topics are taught via facilitated discussions, videos, worksheets, and handouts.
Facilitators are selected by schools and community agencies to receive free trainings conducted by the iDECIDE team, which includes personnel from the Massachusetts Department of Public Health, Massachusetts General Hospital (MGH) Center for Addiction Medicine, and the Institute for Health and Recovery.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Knowledge of drug effects from baseline to 90 day follow-up
Time Frame: Baseline - 90 days
|
Knowledge of drug effects will be measured by number of items correct on a survey examining a student's understanding of adolescent brain development, neurobiology of addiction, and the impact of alcohol, cannabis, nicotine and other substance use on the brain and body.
|
Baseline - 90 days
|
|
Frequency of substance use from baseline to 90 day follow-up
Time Frame: Baseline - 90 days
|
Frequency of substance use will be operationalized as the number of days spent using student's preferred substance assessed via 14-day timeline followback.
|
Baseline - 90 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Emotional support from baseline to 90 day follow-up
Time Frame: Baseline - 90 days
|
Quality of relationships with teachers/administrators, school connectedness, and social and emotional satisfaction at school will be measured using summed scores from the NIH Toolbox Emotional Support Fixed Form Ages 8-17 v2.0, modified to specifically query about emotional support from adults in school.
Raw scores range from 7 to 33 (age- and gender- corrected T-scores also available), with higher scores indicative of more social support.
|
Baseline - 90 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Randi M Schuster, PhD, Massachusetts General Hospital
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2021P002611
- INTF2300H78500224179 (Other Grant/Funding Number: Massachusetts Department of Public Health)
- INTF2400H78500224455 (Other Grant/Funding Number: Massachusetts Department of Public Health)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Substance Use
-
University of ArkansasNational Center for Advancing Translational Sciences (NCATS)RecruitingParenting | Substance Use Treatment | Perinatal Substance UseUnited States
-
Emory UniversityNational Institute on Drug Abuse (NIDA); Georgia Institute of Technology; CUNYCompletedSubstance-Related Disorders | Substance Abuse, Intravenous | Substance Use Disorders | Opioid Use | Substance Abuse | Opioid-use Disorder | Opioid Use Disorder, Severe | Substance WithdrawalUnited States
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA)RecruitingSubstance Use | Substance Use Disorders | Cannabis Use | Alcohol Use, UnspecifiedUnited States
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA)RecruitingTobacco Use | Substance Use DisordersUnited States
-
Wake Forest University Health SciencesNational Institute on Drug Abuse (NIDA)CompletedSubstance Use | Opioid Use | Drug Use | Substance MisuseUnited States
-
Indiana UniversityPatient-Centered Outcomes Research InstituteRecruitingAdolescent | Alcohol Use | Mild Alcohol Use Disorder | Mild Substance Use DisorderUnited States
-
Woebot HealthNational Institute on Drug Abuse (NIDA); Stanford UniversityCompletedSubstance Use Disorders | Alcohol Use Disorder (AUD)United States
-
University of California, San FranciscoTobacco Related Disease Research ProgramRecruitingTobacco Use Disorder | Substance Use Disorder (SUD)United States
-
Icahn School of Medicine at Mount SinaiNational Institute on Drug Abuse (NIDA)Active, not recruitingSubstance Use Disorder | Cocaine Use DisorderUnited States
-
Woebot HealthStanford UniversityCompletedSubstance Use Disorders | Alcohol Use Disorder (AUD)United States
Clinical Trials on iDECIDE (Drug Education Curriculum: Intervention, Diversion, and Empowerment)
-
Massachusetts General HospitalMassachusetts Department of HealthRecruitingSubstance Use | Harm Reduction | Adolescent BehaviorUnited States
-
Colorado State UniversityUniversity of Colorado, Denver; United States Department of Agriculture (USDA) and other collaboratorsRecruitingType 2 Diabetes | Obesity, Adolescent | Mental Health | Adolescent Health | Lifestyle Risk Reduction | Family Health | Wellness Program | Cardio-metabolic HealthUnited States
-
The University of Hong KongCompleted
-
Washington University School of MedicineNational Institute on Alcohol Abuse and Alcoholism (NIAAA)CompletedHIV/AIDS | Drug Use | Adolescent DrinkingUganda
-
Colorado State UniversityUniversity of Colorado, Denver; United States Department of Agriculture (USDA) and other collaboratorsRecruitingMental Health Wellness | Lifestyle Risk Reduction | Family ResearchUnited States
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)CompletedMucositis | Malignant Head and Neck Neoplasm | Radiation-Induced DisorderUnited States